CN1079658A - A kind of traditional Chinese medicine powder capsule for treating chronic ischemic heart disease - Google Patents
A kind of traditional Chinese medicine powder capsule for treating chronic ischemic heart disease Download PDFInfo
- Publication number
- CN1079658A CN1079658A CN 93100577 CN93100577A CN1079658A CN 1079658 A CN1079658 A CN 1079658A CN 93100577 CN93100577 CN 93100577 CN 93100577 A CN93100577 A CN 93100577A CN 1079658 A CN1079658 A CN 1079658A
- Authority
- CN
- China
- Prior art keywords
- present
- group
- chinese medicine
- medicine powder
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 239000002775 capsule Substances 0.000 title claims abstract description 17
- 239000000843 powder Substances 0.000 title claims abstract description 14
- 230000001684 chronic effect Effects 0.000 title claims abstract description 12
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 8
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims abstract description 21
- 239000004870 Styrax Substances 0.000 claims abstract description 21
- 235000000126 Styrax benzoin Nutrition 0.000 claims abstract description 21
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 18
- 241000208340 Araliaceae Species 0.000 claims abstract description 18
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 235000008434 ginseng Nutrition 0.000 claims abstract description 18
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract 3
- 241001061264 Astragalus Species 0.000 claims abstract 3
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract 3
- 240000002943 Elettaria cardamomum Species 0.000 claims abstract 3
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract 3
- 240000000513 Santalum album Species 0.000 claims abstract 3
- 235000008632 Santalum album Nutrition 0.000 claims abstract 3
- 244000028419 Styrax benzoin Species 0.000 claims abstract 3
- 235000006533 astragalus Nutrition 0.000 claims abstract 3
- 229940116229 borneol Drugs 0.000 claims abstract 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract 3
- 235000005300 cardamomo Nutrition 0.000 claims abstract 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract 3
- 210000004233 talus Anatomy 0.000 claims abstract 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract 2
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 claims 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 claims 2
- 244000246386 Mentha pulegium Species 0.000 claims 1
- 235000016257 Mentha pulegium Nutrition 0.000 claims 1
- 235000004357 Mentha x piperita Nutrition 0.000 claims 1
- 235000001050 hortel pimenta Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 241000218176 Corydalis Species 0.000 abstract description 17
- 230000000302 ischemic effect Effects 0.000 abstract description 9
- 230000001154 acute effect Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 5
- 208000019622 heart disease Diseases 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 210000001835 viscera Anatomy 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 238000007596 consolidation process Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 210000002216 heart Anatomy 0.000 description 28
- 241000736148 Styrax Species 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 210000000582 semen Anatomy 0.000 description 17
- 241000628997 Flos Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 239000009636 Huang Qi Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 231100000111 LD50 Toxicity 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000003130 cardiopathic effect Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000153234 Hibiscus abelmoschus Species 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- -1 Pan Xianding Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及治疗慢性缺血性心脏病的中药散剂 胶囊，其特征是胶囊内的纯中药散剂为人参2— 5％，黄芪22—26％，三七1—3％，红花10—14％， 延胡索10—14％，丹参22—26％，檀香6—10％，草 豆蔻10—14％，苏合香0.6—1.0％，冰片0.06— 0.10％，薄荷冰0.02—0.08％。本发明适用于缺血性 心脏病的慢性发作及急性发作后的巩固治疗，保证心 脏正常功能，效果显著，可延长发病周期，减少发病次 数，减轻发病症状，临床实践证明总有效率达93％， 可提高机体免疫力，集治疗与预防为一体。The invention relates to a traditional Chinese medicine powder for treating chronic ischemic heart disease The capsule is characterized in that the pure Chinese medicine powder in the capsule is ginseng 2— 5%, astragalus 22-26%, notoginseng 1-3%, safflower 10-14%, Corydalis 10-14%, Salvia miltiorrhiza 22-26%, Sandalwood 6-10%, Grass Cardamom 10-14%, Styrax 0.6-1.0%, Borneol 0.06- 0.10%, mint ice 0.02-0.08%. The present invention is applicable to ischemic Chronic attack of heart disease and consolidation treatment after acute attack to ensure The normal function of the viscera, the effect is remarkable, can prolong the onset cycle, reduce the number of onset Number, relieve symptoms, clinical practice proves that the total effective rate is 93%, It can improve the body's immunity and integrate treatment and prevention.
Description
The present invention relates to a kind of treatment chronic ischemic heart disease, specifically be applicable to the Chinese herbal medicine powder capsule of the after treatment after cardiopathic chronic outbreak and the acute attack.
At present, along with developing rapidly of Chinese national economy, people's rhythm of life is accelerated day by day, build the ultra-long time work of the moon all the year round, and along with growth in the living standard, the acceleration of social population's senescence, cardiovascular diseases's sickness rate is also more and more higher, and external cardiopathic patient's number also accounts for first of various number of the infecteds all the time.The cardiovascular diseases is worldwide commonly encountered diseases, frequently-occurring disease, so the research treatment is cardiopathic also a lot, clinical medicine such as Pan Xianding, nitroglycerin etc. have been used for, the treatment characteristics are that the speed of taking effect is fast, and are outstanding to acute patient's remission curative effect, had as Riboflavin Tetrabutyrate, metoprolol in recent years again, that distressed medicine such as fixed applies to the cardiovascular diseases in succession is clinical, and be mainly used in diseases such as angina pectoris, its effect is also better, and chemical drugs generally is used for acute patient more, and certain side effect is arranged.Aspect Chinese patent medicine, be used for heart acute disease clinical as SUXIAO JIUXIN DAN, Styrax Pilulae, coronary disease Styrax Pilulae, the main armaticity medical material that uses in this class medicine composition, has happy key, the effect of the mind of waking up, instant effect, effect are also better, but its effect is of short duration, cost an arm and a leg, be not suitable for the chronic heart disease patient and use.The medicine that is used for chronic ischemic heart disease that some are common, as Radix Salviae Miltiorrhizae Tabellae and injection, curative effect such as FUFANG DANSHEN PIAN and injection is limited, new drug in recent years is used for clinical in haydan capsule, DIAOXINXUE KANG, comfortable, heart treasured etc., rare expensive animals and plants are arranged, as the toad Moschus moschiferous in the prescription that these new drugs have.Contain Calculus Bovis, Moschus, Cornu Cervi Pantotrichum etc. in pills for curing heart disease and the heart treasured, and Flos Daturae one class there is certain toxic Chinese crude drug.Also have some Chinese patent medicines only early rich at treatment, or the treatment arrhythmia etc., applicable surface is too narrow again.
The purpose of this invention is to provide that a kind of Chinese medicine thinks to deficiency of heart-QI, flaccidity of the heart-yang, so that QI stagnated by cold, blood stasis and the turbid obstruction of expectorant cause heart arteries and veins obstructed, chest paralysis heart pain, and the myocardial ischemia thought of western medicine, the angina pectoris that anoxia caused, the Chinese patent medicine of treatment such as myocardial infarction usefulness, specifically be applicable to the chronic outbreak of ischemic heart desease and the after treatment after the acute attack, be based on guaranteeing the heart normal function after the heart attack.And the drug prescription Chinese medicine property of medicine is gentle, does not contain rare costliness and virose Chinese crude drug.Take no toxicity for a long time, can increase body's immunity.
The present invention adopts modern capsule for medicine, and Chinese powder medicine prescription and percentage by weight in the capsule are:
Radix Ginseng 2-5%, Radix Astragali 22-26%, Radix Notoginseng 1-3%, Flos Carthami 10-14%, Rhizoma Corydalis 10-14%, Radix Salviae Miltiorrhizae 22-26%, Lignum Santali Albi 6-10%, Semen Alpiniae Katsumadai 10-14%, Styrax 0.6-1.0%, Borneolum Syntheticum 0.06-0.10%, Mentholum 0.02-0.06%.
Chest paralysis heart pain also is an ischemic heart desease, its cardinal symptom for nervous, uncomfortable in chest, chest pain, breathe hard, be the modal frequently-occurring disease of mid-aged population, think according to Chinese medical theory and clinical practice, the basic pathology characteristics of coronary heart disease are " deficiency in origin and excess in superficiality ", " overabundance of pathogen causing excess syndrome, lack of vital essence resulting in deficiency syndrome " is according to this dialectical thought, the deficiency in origin of coronary heart disease is meant the whole body insufficiency of vital energy and blood based on heart, the negative and positive weakness, " mark is real " is meant qi depression to blood stasis on the basis of deficiency in origin, stagnation of phlegm-damp." deficiency in origin " all can cause malnutrition of heart blood with " mark real ", heart arteries and veins impatency and cause nervous, uncomfortable in chest, breathe hard, painedly be the systemic disease of cardinal symptom, should be so treat ischemic heart desease with Qi-benefiting and heart-nourishing, disperse blood stasis and dredge collateral, the chest stuffiness relieving method of treatment of reducing phlegm is an aim.According to the basic pathology of coronary heart disease " deficiency in origin and excess in superficiality " and the pathological characteristic of modern medicine coronary atherosclerosis and spasm, the starting point of treatment is to increase coronary flow, increase the supply of blood flow amount of cardiac muscular tissue, the person reduces myocardial oxygen consumption in addition, improves hypoxia-bearing capability to correct cardiac muscle to the confession of blood oxygen and the balance-loss state of need.So Radix Ginseng, the Radix Astragali are monarch in the prescription of the present invention, consolidate with reinforcing the heart gas, handsome blood operation helps QI regulating medicine to increase the blood stasis dispelling ability.Radix Notoginseng is promoting blood circulation and hemostasis then, and repercussive is in arteries and veins, and promoting the circulation of blood is outside arteries and veins.Blood system falls clearly in Radix Salviae Miltiorrhizae bitter in the mouth cold nature, energy clearing away heat and cooling blood, eliminating blood stasis to promote regeneration of blood.But the gas in the Rhizoma Corydalis promoting the circulation of blood, the blood in the gas can be smooth with hot warm in nature can a surname with QI and blood of gas, and the fragrant row of acrid in the mouth looses.Flos Carthami is gone into the heart, liver two through blood system, and Xin Xianghang is diffusing, and sweet gentleness is smooth, so above four flavors are minister, Lignum Santali Albi, Styrax, Semen Alpiniae Katsumadai phase 5 act on heart spleen for assistant simultaneously, with the blood in regulating the flow of vital energy, help the blood operation, and blood stasis dispellingization stagnates, and Borneolum Syntheticum eliminating cold for resuscitation thinking is treated pained.Mentholum waking up the patient from unconsciousness by clearing away heat thinking, the refresh oneself, soothing liver-QI is strongly fragrant and pain relieving is messenger drug altogether, and the two joins Styrax removing dampness eliminating phlegm, and is vexed to separate brain, breathes hard.The medicine of below respectively distinguishing the flavor of rises altogether and gets final product the beneficial motive, happy key, blood stasis dispersing and phlegm expelling, the effect of removing obstruction in the collateral to relieve pain.All medicines match and complement each other, and are scientific and reasonable, guarantee the curative effect of medicine.
The present invention not only is consistent with China theory of medicine, and also be consistent with modern scientific theory, we are according to Ministry of Health of the People's Republic of China's provisions for new drugs approval pertinent regulations, successively having done the several experiments relevant with pharmacodynamics of the present invention with rabbit, Cavia porcellus, rat and mice, is matched group with the compound Salviae Miltiorrhizae.
Experimental result shows that the present invention of two kinds of dosage and compound Salviae Miltiorrhizae all significantly increase the coronary flow of guinea pig isolated heart, and heavy dose of of the present invention group effect is better than isodose compound Salviae Miltiorrhizae group.
Above experimental result shows, oral still intraperitoneal injection no matter, and the present invention of three groups of various dose can significantly prolong the mice hypoxia endurance time, and effect of the present invention is better than isodose compound Salviae Miltiorrhizae group.
Experimental result shows, the present invention can reduce the viscosity of the high viscosity blood of rabbit due to the macromolecule right rotary glycoside significantly, six of whole blood viscosity different cut speed and two different cutting in the speed of blood plasma, low shear rate has significant difference, high shear rate has significant differences.The present invention can also shorten the time of erythrocyte electrophoresis, and packed cell volume is reduced.
Table 9 the present invention to coronary ligation after the ST field offset influence relatively
| After the ligation | ||||
| 2hr | 1ohr | 24hr | ||
| NST | The heavy dose of group of normal saline group small dose group the present invention of the present invention compound Salviae Miltiorrhizae group | 67 59 53＊ 55＊ | 87 57 57＊ 53＊ | 65 53＊ 49＊＊ 52＊ |
| ΣST (MV) | The heavy dose of group of normal saline group small dose group the present invention of the present invention compound Salviae Miltiorrhizae group | 24.3 15.3 11.8 12.2 | 24.3 13.9 11.2 11.3 | 22.9 12.3 9.5 10.7 |
| ΣST /NST | The heavy dose of group of normal saline group small dose group the present invention of the present invention compound Salviae Miltiorrhizae group | 0.36±0.04 0.26±0.03 0.22±0.0369＊ 0.22±0.0362＊ | 0.36±0.04 0.24±0.05＊ 0.21±0.0358＊ 0.21±0.0417＊ | 0.35±0.04 0.23±0.04＊ 0.19±0.0295＊＊ 0.20±0.044＊ |
| Σ ST/whole mapping points | The heavy dose of group of normal saline group small dose group the present invention of the present invention compound Salviae Miltiorrhizae group | 0.31±0.064 0.19±0.044＊ 0.15±0.047＊ 0.15±0.041＊ | 0.31±0.062 0.18±0.048 0.14±0.042＊ 0.14±0.051＊ | 0.29±0.073 0.16±0.042 0.12±0.033＊ 0.13±0.059 |
＊P＜0.05 ＊＊P＜0.01
Table 10 the present invention to coronary ligation after abnormality Q wave the influence of number appears
| The normal saline group | Small dose group of the present invention | The heavy dose of group of the present invention | The compound Salviae Miltiorrhizae group | |
| NQ NQ wave number accounts for total mapping point % P value | 80 33.3％ | 64 26.7％ 〈0.2 | 55 22.9％ 〈0.15 | 57 23.8％ 〈0.05 |
Table 11 the present invention to coronary ligation after the influence of infarcted myocardium %
| The normal saline group | Small dose group of the present invention | The heavy dose of group of the present invention | The compound Salviae Miltiorrhizae group | |
| Ventricular weight (g) infarcted myocardium weight (g) infarcted myocardium accounts for the % P value of chamber weight whole-heartedly | 3.48 0.76 0.223±0.026 | 3.3 0.49 0.161±0.038 〈0.2 | 3.72 0.46 0.124±0.031 〈0.05 | 3.77 0.47 0.126±0.033 〈0.05 |
Experimental result shows that normal saline group electrocardiogram is cut back 2hr at knot, and the T wave height is alarmmed, and the ST section is raised all clearly, and big small dose group of the present invention and compound Salviae Miltiorrhizae group all are lower than the normal saline group significantly.The ST section is raised total millivolt of number as seen from Table 9, the ST section is raised unusually and is reduced total meansigma methods that number and ST field offset take place and ST field offset divided by whole meansigma methodss of mapping points, small dose group of the present invention all is lower than the normal saline group, and wherein 24hr reduces significant difference (p＜0.05).And the heavy dose of group of the present invention and all remarkable, and heavy dose of of the present invention group of 24hr difference highly significant (p＜0.01) with the compound Salviae Miltiorrhizae group and the normal saline group comparing difference of dosage.
By table 10,11 as seen: number of times that of the present invention group and compound Salviae Miltiorrhizae group pathologic Q ripple occur after the ligation and myocardial infarction NBT dyeing back weighing and normal saline group more all are lower than the normal saline group.Heavy dose wherein of the present invention and compound Salviae Miltiorrhizae group are compared with the normal saline group all has significant difference (p＜0.05).
In above experimental result, NST, ∑ ST/NST are lower than the normal saline group proves that the present invention has the effect of alleviating to the degree and the scope of the myocardial ischemic injury of rabbit experiment.The minimizing of NST, Q ripple and NBT dyeing explanation the present invention and compound Salviae Miltiorrhizae all have the scope of dwindling the myocardial infarction that causes after the hat anterior descending branch ligation of a rabbit left side.And action time of the present invention is lasting than the compound Salviae Miltiorrhizae group.
Acute toxicity test of the present invention is by existing test method, and situation is as follows:
One, mouse stomach medicine-feeding test:
Select 30 of the mices of body weight 20 ± 2g for use, male and female are supported usefulness, and fasting 12 hours is divided into matched group (10), administration group (20) at random.The administration group 4 times on the one, amounts to 50g/kg/ day with the suspension oral gavage of the present invention of the maximum volume (0.5ml/10g) of Cmax (25%).Matched group is irritated stomach with the equal-volume normal saline.Raised and observe seven under about 20 ℃ of room temperatures after the administration, beginning animal food-intake is less slightly, recovers normal two days later, drinking-water, activity.All no abnormal phenomenon such as body weight, hair color etc. is put to death organs such as the animal perusal heart, liver, spleen, lung, kidney, relatively has no significant change with matched group.So the dosis tolerata of mice is 50g/kg, obtains the dosis tolerata multiple of mice by following formula.
The dosis tolerata multiple of mice=(every mouse tolerance dose)/(mice average weight) * (adult's average weight (60,000g))/(adult's consumption every day)
The dosis tolerata of mice is 750 times of people's consumption.
Two, mouse peritoneal drug administration by injection test
Get 50 of mices earlier, male and female half and half are divided into 5 groups at random, every group 10, with five dosage lumbar injection extracting solution of the present invention, feeding conditions is with irritating the stomach group, the performance of injection rear section mice is quiet, has the part mice to begin death after 7 hours, its phenomenon finding during with prerun.After the medication 24 hours, death no longer takes place in the mice of survival, and survival mice was recovered normally to look for food etc. movable after 1 to 3 day, continues to observe to the 7th day none death.The mice of death was dissected in half an hour, see intestinal tube and near organize slightly hyperemia and minute quantity to be dispersed in the petechia, other internal organs naked eyes show no obvious abnormalities.Dissect the mice that survived in the 7th day after the medication, the finding of naked eye of its heart, liver, kidney, lung, stomach, identical with the mice of not medication, the results are shown in Table 1.
i＝0.0757
Adopt the simplification probit method to try to achieve the median lethal dose(LD 50) of mouse peritoneal injection of the present invention according to the mouse death rate of respectively organizing behind lumbar injection the present invention:
Be LD50=20.3823g/kg
95% average fiducial limit=20.3823 ± 1.0359g/kg of LD50
Fig. 1 is that acute toxicity test of the present invention is by existing test method, " the coordinate curve chart of rat body weight (g) change list before and after the administration of the present invention; wherein ordinate is represented the weight of animals (g); the time (natural law) that on behalf of animal, abscissa take medicine; under identical conditions is raised the situation of change of observing administration group (three dosage) and matched group body weight after 75 days to second mouse peritoneal drug administration by injection test invading the exterior 13.
By in above four tables as can be seen, though hemoglobin, RBC number, leukocyte count and platelet fluctuate, all within range of normal value, the also no abnormal variation of the measurement result of leukocyte differential count.Prompting the present invention does not have bad influence to hemopoietic system and surrounding hemogram.
* suffer from the otitis media deselect because of a rat;
* has two because of suffering from the otitis media deselect.
Above experimental result shows that each is organized serum glutamic pyruvic transminase, total protein, albumin, globulin, the blood urea nitrogen of administration animal and compares no significant difference with matched group.Other detects jaundice index between 2-5, and thymol all between 1-5, this shows that the present invention does not have overt toxicity to the hepatic and renal function of rat.
Three, tissue slice is observed
After the drug withdrawal, rat divides that two batches of execution (at interval two weeks) are cored, liver,spleen,kidney, stomach, lung, with formaldehyde fixed HE dyeing, carries out tissue slice under 400 power microscopes and observes.First heart, liver, spleen, lung, kidney, the overwhelming majority of stomach texture all belong to normal structure as a result.One example is only arranged, heavy dose of group slight hepatic cell cloudy swelling, heavy dose of group and matched group respectively have a routine bronchial chronic inflammation to change.The animal of second batch of execution only has a routine matched group that the pathological change of chronic bronchitis is arranged, and other tissue slice is normally.
Show that from each time result of the test of above long term toxicity test of the present invention the present invention does not influence the normal growth growth of rat and the normal growth of body weight; The every index of peripheral hemogram is normally, and prompting does not influence the hemopoietic function of rat; Do not reduce liver, stomach function.Behind the sacrifice of animal, the size of the perusal heart, liver, spleen, lung, kidney, stomach, surface and hardness are all no abnormal.Tissue slice checks that the heart, spleen, kidney, all no abnormal pathologic of stomach four internal organs officials change.Only have first to put to death the heavy dose of group of animal hepatocyte slight cloudy swelling is arranged, second batch of no abnormal pathological changes can cause reversible slight poisoning when pointing out excess dosage of the present invention.The heavy dose of example of the rat of first execution, matched group two examples have the chronic bronchitis reason to change.This is owing to stop sending in raising due to heating installation catches a cold.More than explanation the present invention is a Chinese patent medicine that safety is big, toxicity is little.
Clinical observation of the present invention, " the national coronary heart disease opinion take stopgap measures standard " of working out with reference to China on tcm diagnosis and the typing and " angina pectoris Chinese medical discrimination tentative standard ", and clinical practice experience, differentiation of symptoms and signs for classification of syndrome, be divided into four kinds of deficiency of both QI and YIN, qi stagnation and blood stasis type, type of stagnation of phlegm-damp, mixed type, and in the clinical practice, simple type is less, and compound is many.And, reach related standards and carry out efficacy evaluation according to " angina pectoris and ECG curative effect evaluation criteria " that China works out.By clinical observation checking, the type of deficiency of both QI and YIN produce effects be 62.5%, effectively be 37.5%, the qi stagnation and blood stasis type produce effects be 100%, the type of stagnation of phlegm-damp produce effects be 66.67%, effectively be 33.33%, the mixed type produce effects is 82.75%, effectively is 17.24%.Simultaneously from above four types as can be seen total effective rate be 100%, through using the hypergeometry probability calculation, P＜0.05, further carrying out per two groups compares, significant difference P＜0.05 is arranged between type of deficiency of both QI and YIN and the qi stagnation and blood stasis type, and all the other per two groups are compared difference that there are no significant, P＞0.05 illustrates in " ischemic heart desease " traditional Chinese medical science typing best with the qi stagnation and blood stasis type curative effect.
Table 23 62 examples " ischemic heart desease " traditional Chinese medical science typing curative effect relatively
| Produce effects | Effectively | Invalid | Add up to | |
| Type of deficiency of both QI and YIN qi stagnation and blood stasis type type of stagnation of phlegm-damp mixed type adds up to | 5 22 2 24 53 | 3 0 1 5 9 | 0 0 0 0 0 | 8 22 3 29 62 |
| The P value | 0.01195 | |||
By table 24 as seen, the present invention to " ischemic heart desease " patient nervous, uncomfortable in chest, breathe hard, angina pectoris, heart failure, abnormality T wave, S-T ↓ etc. symptom all improve significantly, before and after the treatment size scale, x
2Check, P＜0.005, wherein remarkable to breathe hard, P＜0.05 has highly significant difference.
The present invention can be a year and a half in normal temperature condition following storage period, and its character, discriminating, content, moisture all fluctuate in acceptability limit.
Chinese powder medicine prescription in the capsule of the present invention, it presses the property classification of Chinese medicine, and available one or more other Chinese crude drugs with quasi-medicated property substitute, can substitute the in like manner Radix Astragali and Rhizoma Polygonati, Radix Notoginseng and Pseudobulbus Bletillae (Rhizoma Bletillae) with Radix Codonopsis such as Radix Ginseng, Flos Carthami and Semen Persicae, Rhizoma Corydalis and Radix Curcumae, Radix Salviae Miltiorrhizae and Rhizoma Chuanxiong, Lignum Santali Albi and Lignum Dalbergiae Odoriferae, Semen Alpiniae Katsumadai and Fructus Amomi, Styrax and Benzoinum, Borneolum Syntheticum and Rhizoma Acori Graminei, all interchangeable replacement of Mentholum and Herba Menthae.
Chinese powder medicine in every capsules of the present invention weighs 0.4 gram, and the ischemic heart patient takes 2 to 4 at every turn, every day three times or follow the doctor's advice.
Powder prescription in the capsule of the present invention can be used for tablet, pill, decoction, electuary, oral liquor and other types of formulations simultaneously.
The present invention stipulates according to Pharmacopoeia of People's Republic of China, carries out the formulation of the quality standard of method for making, discriminating, inspection one by one, has augmented content assaying method simultaneously.
Advantage of the present invention is to have benefiting QI and nourishing blood to have one's ideas straightened out, the effect of blood-activating analgetic is applicable to the chronic outbreak of ischemic heart desease and the after treatment after the acute attack, guarantees the heart normal function, effect is remarkable, can prolong disease cycle, reduce the morbidity number of times, alleviate disease symptom, clinical practice proof total effective rate reaches 93%, taking no toxicity for a long time, and the function of human body immunity improving power is arranged, is that the collection treatment is the good medicine of one with prevention.The present invention does not contain the animals and plants of rare costliness, does not contain virose Chinese crude drug yet, and is with low cost, and taking convenience is easy to be accepted by society.
Embodiment
Embodiment one:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Its method for making is earlier Rhizoma Corydalis to be soaked with 0.5% HCI, acid immersion after the immersion is neutralized into neutral immersion (1) with NaOH solution, medicinal residues after the immersion of Rhizoma Corydalis are incorporated Radix Salviae Miltiorrhizae, the Radix Astragali, Flos Carthami mixing back decocting into, fry in shallow oil after-filtration, filtrate is mixed with neutral immersion (1) again, mixed solution is through being condensed into the thick paste shape, mix mutually with Radix Ginseng, Radix Notoginseng, Semen Alpiniae Katsumadai, Lignum Santali Albi fine powder after crushed again and mix thoroughly, and drying is pulverized, add the alcoholic solution of Styrax, Borneolum Syntheticum, Mentholum again and mix thoroughly semi-finished product, with the semi-finished product filling in capsule finished product.
Embodiment two:
Radix Codonopsis 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment three:
Radix Ginseng 4.01%, Rhizoma Polygonati 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment four:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Pseudobulbus Bletillae (Rhizoma Bletillae) 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment five:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Semen Persicae 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment six:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Radix Curcumae 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment seven:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Rhizoma Chuanxiong 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment eight:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Dalbergiae Odoriferae 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment nine:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Fructus Amomi 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment ten:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Benzoinum 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment 11:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Rhizoma Acori Graminei 0.08%, Mentholum 1.04%.
Embodiment 12:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Herba Menthae 1.04%.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100577A CN1041494C (en) | 1993-01-01 | 1993-01-01 | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100577A CN1041494C (en) | 1993-01-01 | 1993-01-01 | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1079658A true CN1079658A (en) | 1993-12-22 |
| CN1041494C CN1041494C (en) | 1999-01-06 |
Family
ID=4983105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93100577A Expired - Fee Related CN1041494C (en) | 1993-01-01 | 1993-01-01 | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1041494C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505936A (en) * | 2003-09-23 | 2007-03-15 | ティアンジン タスリー ファーマシューティカル カンパニー リミテッド | Pharmaceutical compositions for the treatment of cardiovascular and cerebrovascular diseases |
| CN1313565C (en) * | 2004-07-23 | 2007-05-02 | 北京化工大学 | Rare earth/polymer composite luminous material and its preparation method |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486464B2 (en) * | 2000-12-22 | 2013-07-16 | Tasly Pharmaceutical Group Co. Ltd. | Herbal composition for angina pectoris, method to prepare same and uses thereof |
| US20050037094A1 (en) | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
-
1993
- 1993-01-01 CN CN93100577A patent/CN1041494C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505936A (en) * | 2003-09-23 | 2007-03-15 | ティアンジン タスリー ファーマシューティカル カンパニー リミテッド | Pharmaceutical compositions for the treatment of cardiovascular and cerebrovascular diseases |
| EP1679058A4 (en) * | 2003-09-23 | 2009-12-09 | Tianjin Tasly Pharmaceutical | Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases |
| JP4943846B2 (en) * | 2003-09-23 | 2012-05-30 | ティアンジン タスリー ファーマシューティカル カンパニー リミテッド | Pharmaceutical compositions for the treatment of cardiovascular and cerebrovascular diseases |
| CN1313565C (en) * | 2004-07-23 | 2007-05-02 | 北京化工大学 | Rare earth/polymer composite luminous material and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1041494C (en) | 1999-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1041494C (en) | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease | |
| CN116898897B (en) | Primordial qi-tonifying, hypoxia-resisting and chronic fatigue-conditioning primordial qi-preserving soup recipe and preparation method thereof | |
| CN1175893C (en) | Medicine for treating child multiacting disease and its preparation method | |
| CN1087272A (en) | A kind of traditional Chinese medicine powder capsule for treating chronic ischemic heart disease | |
| CN1772196A (en) | Heart failure regulating Chinese medicine | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN103272111A (en) | Traditional Chinese medicine liquor for treating toothache | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN108935694A (en) | A kind of healthcare goat milk powder and preparation method thereof with antifatigue simultaneous void of enriching blood | |
| CN102626510A (en) | Traditional Chinese medicine composite for treating diabetic cardiopathy and preparation method and applications of traditional Chinese medicine composite | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1698869A (en) | Shenbai Ningshen Oral Liquid | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN1520859A (en) | Cerebrovascular and cardiovascular disease treating injection containing red-rooted salvia and safflower | |
| CN1242766C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof | |
| CN1709476A (en) | Yang Xin An Mian Capsules | |
| CN1059583C (en) | Oral liquid of Chinese medicine for deficiency syndrome | |
| CN1247237C (en) | Medicinal composition for treating coronary disease and its preparation and application | |
| CN1270764C (en) | Medicine for treating liver disease and its preparation method | |
| CN1513539A (en) | Preparation technology of supplementing kind capsule | |
| CN1183297A (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN106344758A (en) | Lam's sugar reducing formula | |
| CN1256083C (en) | Medicine for boosting qi and nourishing blood and its prepatation method | |
| CN119113060A (en) | A Chinese medicine composition for treating AIDS and strengthening the body and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |